SLS

Sellas Life Sciences Group Inc

Add to Watchlist

Advanced Chart

1.830

-0.01(-0.543%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.880

Open

1.830

VWAP

1.81

Vol

1.96M

Mkt Cap

303.34M

Low

1.750

Amount

3.54M

EV/EBITDA(TTM)

Total Shares

57.75M

155.19M

EV/OCF(TTM)

P/S(TTM)

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

2 Analyst Rating

214.21% Upside

Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 5.75 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

214.21% Upside

Current: 1.830

Low

4.00

Averages

5.75

High

7.50

214.21% Upside

Current: 1.830

Low

4.00

Averages

5.75

High

7.50

Maxim

Buy

maintain

$4 -> $7

2025-07-16

Reason

Maxim

Price Target

$4 -> $7

2025-07-16

maintain

Buy

Reason

Maxim raised the firm's price target on Sellas Life Sciences to $7 from $4 and keeps a Buy rating on the shares. Shares have risen about 90% year-to-date as the company continues to execute across its Acute Myeloid Leukemia, or AML, programs, the analyst tells investors in a research note. Maxim further cites the company's galinpepimut-S in Phase 3 and yesterday's positive SLS009 data hitting all its endpoints, adding that its higher price target factors in SLS009 in first-line AML as a potential triplet combination with venetoclax/azacitidine.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sellas Life Sciences Group Inc (SLS.O) is -5.36, compared to its 5-year average forward P/E of -3.33. For a more detailed relative valuation and DCF analysis to assess Sellas Life Sciences Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.33

Current PE

-5.36

Overvalued PE

-1.21

Undervalued PE

-5.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.09

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.33

Undervalued EV/EBITDA

-0.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.57

Current PS

0.00

Overvalued PS

32.88

Undervalued PS

-11.73